Anesthesia

"[4] (b) Effects of Trendelenburg and reverse Trendelenburg positions during laparoscopic surgery [3] (c) Specific complications of laparoscopic surgery and their management [3]. A. Physiological Effects of CO₂ Pneumoperitoneum 4 marks ⚙ Core Concept CO₂ pneumoperitoneum (standard insufflation pressure 12–15 mmHg) produces complex and sometimes opposing haemodynamic effects — a combination of: mechanical effects of raised intra-abdominal pressure (IAP) + systemic absorption of CO₂ + neurohumoral responses (vasopressin, catecholamine, renin-angiotensin activation from peritoneal stretch). (Joris JL — haemodynamics of laparoscopy; Cunningham AJ; Miller's Anaesthesia 9th Ed) System Effect of CO₂ Pneumoperitoneum Mechanism Clinical Management CVS — venous return (preload) Initial ↑ then ↓ venous return; biphasic response; at low IAP (<10 mmHg): splanchnic blood squeezed into central circulation → ↑ preload; at high IAP (>20 mmHg): IVC compression → ↓ venous return → ↓ CO Mechanical compression of IVC at high IAP; initial splanchnic mobilisation at low IAP Standard IAP 12–15 mmHg (below IVC compression threshold); fluid preload before pneumoperitoneum in hypovolaemic patients CVS — SVR (afterload) ↑ SVR — most consistent haemodynamic effect of pneumoperitoneum; SVR ↑ 25–35% Mechanical compression of aorta + mesenteric vasculature; neurohumoral: ↑ vasopressin (ADH) from peritoneal stretch → potent vasoconstriction; ↑ catecholamines + ↑ renin-angiotensin ↑ SVR + maintained CO → ↑ MAP → watch for hypertension in hypertensive patients; deepening anaesthesia or vasodilators if severe CVS — heart rate and CO ↑ HR (vagal reflexes on peritoneal insufflation → brief bradycardia → then tachycardia from ↑ sympathetic tone); CO may be maintained or slightly ↓ depending on balance of preload/afterload changes Peritoneal stretch → vagal reflexes at insufflation (bradycardia, rarely asystole → STOP insufflation + atropine if severe); catecholamine-mediated tachycardia thereafter Inform surgeon to PAUSE insufflation if severe bradycardia; atropine 0.6 mg IV; monitor ECG throughout Respiratory — compliance ↓ Respiratory compliance (20–40%): diaphragm pushed cephalad by abdominal distension → lungs compressed → ↓ FRC → ↓ compliance → ↑ airway pressure for same TV; V/Q mismatch → ↑ shunt → hypoxaemia risk Cephalad diaphragm displacement; atelectasis; ↑ gas trapping in dependent zones Pressure-controlled ventilation preferred (limits barotrauma from compliance changes); PEEP 5–10 cmH₂O; ↑ FiO₂; reduce TV + ↑ RR if needed CO₂ absorption CO₂ absorbed from peritoneum → ↑ PaCO₂ → hypercapnia (PaCO₂ ↑ by 5–10 mmHg during standard laparoscopy); ↑ ETCO₂ (reliable monitor of PaCO₂ unless V/Q mismatch is significant); ↑ minute ventilation required (↑ 15–30%) to maintain normocarbia CO₂ is highly diffusible across peritoneal membrane; blood-gas solubility of CO₂ is 20× O₂ — rapidly absorbed; CO₂ insufflation chosen over air/N₂ because: rapid absorption (prevents gas embolism persistence), non- combustible (safe with diathermy), non-irritant ↑ MV by 15–30% (↑ RR rather than TV to avoid barotrauma); monitor ETCO₂ continuously; if sudden ↑↑ ETCO₂ → consider CO₂ embolism (see below) B. Position Effects — Trendelenburg and Reverse Trendelenburg 3 marks Position Used For Physiological Effects Anaesthetic Concerns Trendelenburg (head-down 15–30°) Lower abdominal and pelvic laparoscopic surgery (colorectal, gynaecological, robotic prostatectomy — often steep 30– 40° Trendelenburg) Viscera shift cephalad → ↑ further cephalad displacement of diaphragm (on top of pneumoperitoneum effect) → ↓↓ FRC → atelectasis → ↑↑ airway pressure; improved venous return → ↑ CO (partially counteracts pneumoperitoneum effect); ↑ ICP (↑ venous pressure in head/neck → ↑ cerebral venous congestion → ↑ ICP → risk of visual loss from ischaemic optic neuropathy in steep prolonged Trendelenburg — robotic prostatectomy); ↑ oedema of face, airway, conjunctivae (prolonged position) Tube position check after positioning (tracheal tube may migrate into right main bronchus as carina moves cephalad); ↑ airway pressures → adjust ventilator; ETT preferred over LMA (higher leak pressure required); facial oedema → check airway before extubation; post-op visual loss: rare but described (CRAO, AION) in robotic prostatectomy — inform patient pre-operatively; extreme Trendelenburg contraindicated in: ↑ ICP, severe cardiac disease (↑ preload may precipitate APO) Reverse Trendelenburg (head-up 15– 20°) Upper abdominal laparoscopy (cholecystectomy, fundoplication, bariatric surgery — allows viscera to fall away from operative field) Viscera fall caudally → diaphragm descends → ↑ FRC (partially offsets pneumoperitoneum compression); ↓ venous return → ↓ preload → ↓ CO → ↓ MAP; pooling of blood in lower extremities Hypotension — most common problem; fluid preload before positioning; vasopressors (phenylephrine/ephedrine); monitor MAP continuously; leg compression stockings (prevent stasis + pooling) C. Specific Complications of Laparoscopic Surgery 3 marks Complication Mechanism Clinical Presentation Management CO₂ embolism (gas embolism) CO₂ enters a vessel (hepatic vein, IVC) directly via Veress needle or trocar → gas lock in right heart → ↓ CO → cardiovascular collapse; less lethal than air embolism (CO₂ absorbed quickly) but still potentially fatal with large volumes Sudden ↓↓ ETCO₂ (not ↑ — gas lock prevents CO₂ delivery to lungs → ETCO₂ falls) + ↓ SpO₂ + ↓ BP + mill-wheel murmur (churning sound in heart) + ECG changes; the sudden FALL in ETCO₂ with cardiovascular collapse = CO₂ embolism until proven otherwise IMMEDIATELY: tell surgeon STOP insufflation + desufflate; Durant's manoeuvre — left lateral decubitus + head-down (moves gas bubble away from RV outflow tract); 100% O₂; CPR if cardiac arrest; aspiration via central venous catheter (if in situ) of gas; DO NOT use N₂O (expands gas embolism) Surgical emphysema (subcutaneous CO₂) CO₂ leaks from peritoneum into subcutaneous tissue (misplaced Veress needle, trocar site leakage) → crepitus; if extensive → mediastinal emphysema → pneumothorax; → ↑↑ CO₂ absorption → severe hypercapnia Crepitus on palpation of chest/neck; ↑↑ ETCO₂ (large CO₂ absorption from subcutaneous tissue); may cause airway compromise if extensive cervical emphysema Inform surgeon; desufflate if severe; ↑ ventilation; usually self-resolving; if pneumothorax → intercostal drain Visceral or vascular injury Veress needle or trocar insertion injury to bowel, major vessel (aorta, IVC), bladder — may not be immediately apparent; major vascular injury → haemorrhage → haemodynamic collapse Unexplained hypotension; failure to achieve adequate pneumoperitoneum (gas escaping into vessel); bloody aspirate from Veress needle before insufflation Immediate: surgeon recognises and converts to open; massive transfusion protocol; vascular surgeon call; anaesthetic management of haemorrhagic shock Bradycardia/vagal arrest Rapid peritoneal insufflation → peritoneal stretch → vagal reflex → severe bradycardia or asystole; more common with rapid insufflation or high IAP Sudden bradycardia/asystole during insufflation; ECG monitoring shows sudden HR drop STOP insufflation (tell surgeon immediately); atropine 0.6 mg IV; if cardiac arrest → CPR; desufflate; usually responds promptly ★ Examiner's Pearl CO₂ pneumoperitoneum: ↑ SVR (25–35%) + ↓ compliance (20–40%) + ↑ PaCO₂ (need ↑ MV 15–30%). CO₂ embolism: FALL in ETCO₂ (not rise) + cardiovascular collapse = gas lock; Durant's manoeuvre (left lateral + head-down). Trendelenburg: ↑ ICP → post-op visual loss risk in robotic prostatectomy (AION/CRAO); tube migration into RMB. Reverse Trendelenburg: ↓ preload → hypotension. Bradycardia at insufflation → STOP insufflation + atropine. References: Joris JL et al. Haemodynamic changes during laparoscopic cholecystectomy (Anesth Analg 1992;76:1067-1071). Cunningham AJ, Brull SJ. Laparoscopic cholecystectomy — anaesthetic implications (Anesth Analg 1993;76:1120-1133). Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 75."

"ASRA/ESRA recommended time intervals for neuraxial blocks and anticoagulant drugs [5] (c) Regional anaesthesia in the setting of thrombocytopenia and antiplatelet agents [2]. A. Epidural Haematoma 3 marks ⚙ Core Concept Epidural haematoma is the most feared complication of neuraxial anaesthesia — while rare (1:150,000 for epidurals; 1:220,000 for spinals — Cook TM NAP3), it causes potentially permanent neurological injury. The time from symptom onset to surgical decompression is the single most important determinant of neurological outcome. (Cook TM — NAP3; Horlocker TT — ASRA guidelines 4th Ed 2018; ESRA guidelines 2021) Incidence: NAP3 (Cook TM, Br J Anaesth 2009): 1 in 150,000 epidurals; 1 in 220,000 spinals; highest risk: thoracic epidurals in anticoagulated patients (1 in 3,600 in some series) Risk factors: anticoagulation (LMWH, UFH, warfarin, NOACs, antiplatelets — the most important modifiable risk factor); coagulopathy (INR >1.5; platelets <80×10⁹/L); technical difficulty (multiple attempts, bloody tap — risk ↑ 50% with traumatic insertion); patient factors: female sex, older age, spinal stenosis (smaller epidural space), underlying coagulopathy; catheter removal is equally high risk as insertion (same haemostatic disruption — LMWH timing applies equally to catheter removal) Clinical presentation — VIGILANCE IS KEY: back pain (new, severe, out of proportion — may be the first sign); neurological deficit (lower limb weakness, urinary retention, sensory loss, bilateral symptoms); the pattern: BACK PAIN → RADICULOPATHY → ASCENDING WEAKNESS/PARAPLEGIA; time course: usually within 72 hours of catheter insertion or removal Time-critical management: Immediate clinical assessment: ask specifically about new back pain, leg weakness, urinary/bowel change in ALL patients with epidural catheters on every clinical review URGENT MRI spine (NOT CT — superior soft tissue resolution; can be performed within 30–60 min in most centres): confirms diagnosis (hyperintense collection compressing cord on T2) Neurosurgical decompression (emergency laminectomy/haematoma evacuation) within 6–8 hours of onset of neurological deficit — the critical window; if decompressed within 8h: >60% make complete or near-complete recovery; >24h delay: <10% full recovery; inform neurosurgeons IMMEDIATELY when haematoma is suspected — do not wait for MRI confirmation before calling Reverse anticoagulation (vitamin K + PCC for warfarin; protamine for UFH/LMWH; idarucizumab for dabigatran; andexanet alfa for Xa inhibitors) to allow safe surgical access B. ASRA/ESRA Time Intervals for Neuraxial Blocks 5 marks Drug Stop BEFORE Block Restart AFTER Block/Catheter Removal Key Notes LMWH prophylactic (e.g., enoxaparin 40 mg OD) 12 hours before 6–12 hours after Most common clinical scenario; check anti-Xa if renal failure (accumulation); once-daily dosing preferred (lower anti-Xa peaks) LMWH therapeutic (e.g., enoxaparin 1 mg/kg BD) 24 hours before 24 hours after Therapeutic anticoagulation → longer hold; ensure anti-Xa level undetectable before proceeding UFH (unfractionated heparin) IV infusion Stop 4–6 hours before; check APTT (must be normal range) 1 hour after UFH has short half-life; confirm APTT normalised; intraoperative heparin after neuraxial: wait ≥60 min after epidural/spinal before giving IV heparin UFH subcutaneous prophylactic (5,000U BD/TDS) 4–6 hours before 1 hour after May cause thrombocytopenia (HIT) with prolonged use → check platelet count >80 if on UFH >4 days Warfarin Stop 5 days before; check INR <1.4 on day of procedure After catheter removal when INR <1.5 Monitor INR daily while catheter in situ (if patient restarted warfarin postoperatively, remove catheter when INR <1.5); bridging with LMWH if necessary Dabigatran (direct thrombin inhibitor) CrCl ≥80: 72h; CrCl 50–79: 96h; CrCl 30– 49: 120h; CrCl <30: NOT recommended for neuraxial 6 hours after Renal elimination dominant → dose-dependent accumulation in renal failure; dTT or TT (thrombin time) can confirm adequate clearance; idarucizumab for reversal Rivaroxaban (Factor Xa inhibitor) Standard dose (20 mg OD): 72h before; prophylactic dose (10 mg OD): 22–26h before 6 hours after Anti-Xa assay can confirm clearance (calibrated for rivaroxaban); andexanet alfa for reversal Apixaban (Factor Xa inhibitor) Standard dose: 72h before; prophylactic dose: 26–30h 6 hours after Similar to rivaroxaban; no widely available reversal assay; andexanet alfa for reversal Fondaparinux (indirect Xa inhibitor) 36–42h before (T½ = 17–21h) 6–12h after Long half-life; renal elimination; no reversal agent; ASRA considers it acceptable if strict timing observed; avoid in renal failure Thrombolytics (alteplase, streptokinase) ABSOLUTE CONTRAINDICATION to neuraxial within 10 days of thrombolytic administration 10 days after Systemic fibrinolysis → catastrophic haematoma risk; emergency situations only — weigh benefit vs risk; fibrinogen and plasminogen levels may remain low for days C. Thrombocytopenia and Antiplatelet Agents 2 marks Thrombocytopenia thresholds for neuraxial: platelets ≥80×10⁹/L → neuraxial generally safe (ASRA Grade 2C); platelets 50–80×10⁹/L → individual risk- benefit assessment; platelets <50×10⁹/L → neuraxial contraindicated (insufficient platelet plug); platelets <20×10⁹/L → even peripheral nerve blocks may carry significant bleeding risk; note: platelet COUNT is only one factor — platelet FUNCTION also matters (uraemic platelets, GPIIb/IIIa inhibitors → dysfunctional despite adequate count) Antiplatelet agents: aspirin alone (75–300 mg OD) — DOES NOT increase epidural haematoma risk; neuraxial safe with aspirin monotherapy (ASRA consensus); NSAIDs — similarly no ↑ risk with monotherapy; clopidogrel (P2Y12 inhibitor) — stop 7 days before neuraxial; ticagrelor — stop 5 days; prasugrel — stop 7 days; dual antiplatelet therapy (aspirin + clopidogrel) → ↑ risk — stop P2Y12 agent per above intervals; GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) — stop 24–48h (abciximab 48h; others 8–10h) before neuraxial due to profound platelet inhibition Viva Corner Q. A patient on rivaroxaban 20 mg OD presents at 4 AM for emergency hip fracture surgery requiring spinal anaesthesia. Her last dose was 18 hours ago. What is your decision? This is a genuine clinical dilemma that requires careful risk-benefit analysis rather than rigid adherence to a time interval. The ASRA/ESRA recommendation for rivaroxaban 20 mg OD is 72 hours before neuraxial block — the patient has only had 18 hours since her last dose, which is far shorter than the recommended interval. The pharmacokinetics of rivaroxaban: bioavailability 80–100%; half-life 5–9 hours in young patients, up to 13 hours in elderly; renal elimination 33–66% unchanged; at 18 hours post-dose (approximately 2–3 half-lives), approximately 25–12.5% of the drug remains active — this represents a clinically significant residual anti-Xa effect. My decision: I would NOT perform spinal anaesthesia at this time. The residual rivaroxaban at 18 hours is too high to safely perform neuraxial anaesthesia — the risk of epidural haematoma causing permanent paraplegia outweighs the benefit of a spinal technique. My plan: perform the surgery under general anaesthesia (RSI with propofol + rocuronium — hip fracture patients are high aspiration risk from pain + opioids + full stomach); supplement with regional analgesia using a femoral nerve block or FICB (fascia iliaca compartment block) — these are peripheral nerve blocks where the consequences of a haematoma are less catastrophic than intraspinal haematoma; apply haemostatic measures during surgery (tranexamic acid routinely for hip fracture surgery — NICE recommends TXA for hip fracture). If anti-Xa assay is immediately available (calibrated for rivaroxaban): if peak-to-trough ratio confirms <0.1 IU/mL (near-undetectable) → could re-consider spinal with neurosurgical back-up plan in place and intensive post-operative monitoring; however this assay is not universally available at 4 AM. Post- operatively: restart rivaroxaban as DVT prophylaxis per orthopaedic team guidance (typically 6–12h post-op). ★ Examiner's Pearl Epidural haematoma: decompression within 6–8 hours = best recovery (60%+ complete); >24h = <10% full recovery → urgent MRI + immediate neurosurgical call. LMWH: 12h (prophylactic) or 24h (therapeutic) before neuraxial; 6–12h after. Warfarin: 5 days stop; INR <1.4 before; remove catheter when INR <1.5. NOACs: rivaroxaban/apixaban 72h (standard dose); dabigatran 72–120h depending on CrCl. Aspirin ALONE: no increased neuraxial risk. Clopidogrel: 7 days stop. Thrombolytics: ABSOLUTE CONTRAINDICATION within 10 days. References: Cook TM et al. NAP3 (Br J Anaesth 2009;102:179-190). Horlocker TT et al. ASRA Practice Advisory on Regional Anesthesia and Anticoagulation, 4th Ed (Reg Anesth Pain Med 2018;43:263-309). ESRA Neuraxial Anaesthesia and Anticoagulation Guidelines 2021. Miller RD et al. Miller's Anaesthesia, 9th Ed."

"patient-controlled analgesia (PCA) — standard parameters, opioid selection and safety features [4]. Outline a multimodal analgesic strategy for major abdominal surgery [3]. ⚙ Core Concept Acute postoperative pain is undertreated in 50% of surgical patients — with consequences including immobility, atelectasis, DVT, poor wound healing, and progression to chronic post-surgical pain (CPSP). A multimodal approach (combining analgesics with different mechanisms to achieve additive/synergistic analgesia with reduced individual drug doses and side effects) is the evidence-based standard. (WHO analgesic ladder 1986; Kehlet H — multimodal analgesia; PROSPECT guidelines; Rawal N — PCA pharmacology) A. WHO Analgesic Ladder — Application to Acute Pain 3 marks WHO ladder (1986) — originally for cancer pain, now adapted for acute postoperative pain: Step 1 (mild pain — VAS 1–3/10): non-opioid analgesics — paracetamol (1g QDS IV or oral) ± NSAIDs/COX-2 inhibitors (ibuprofen 400 mg TDS, diclofenac 75 mg BD, celecoxib 200 mg BD — contraindicated in: renal impairment, peptic ulcer disease, cardiovascular disease, post-GI surgery, pregnancy >30 weeks) Step 2 (moderate pain — VAS 4–6/10): weak opioid ± non-opioid — codeine 30–60 mg 4-hourly (hepatically metabolised to morphine via CYP2D6 — ultra-rapid metabolisers [10% of Caucasians] → toxic morphine levels; poor metabolisers → no analgesia; therefore codeine is unpredictable; tramadol 50–100 mg QDS — dual mechanism: weak μ agonist + SNRI; serotonin syndrome risk with SSRIs/MAOIs) Step 3 (severe pain — VAS 7–10/10): strong opioid ± non-opioid ± adjuvants — morphine, oxycodone, fentanyl, hydromorphone; PCA (see below); IV patient-titrated loading boluses (titrate 2–5 mg morphine IV every 5 min until VAS ≤3) Adaptation for acute postoperative pain: the WHO ladder is used in REVERSE for acute pain (Step 3 first, then stepping DOWN as pain improves) — this is the ""reverse ladder"" concept; pre-operatively: anticipate pain intensity and plan multimodal strategy rather than reacting to pain after it occurs (pro-active vs reactive analgesia) Adjuvants at any step: gabapentinoids (pregabalin 150 mg BD, gabapentin 300 mg TDS — ↓ central sensitisation, ↓ opioid requirements, ↓ PONV; most useful in neuropathic or chronic pain component); ketamine sub-anaesthetic infusion (0.1–0.2 mg/kg/h — NMDA antagonist, prevents central sensitisation, reduces opioid requirements); α₂ agonists (clonidine, dexmedetomidine — spinal and systemic analgesia) B. Patient-Controlled Analgesia (PCA) Pharmacology 4 marks PCA rationale: analgesic requirements vary 5-fold between patients of the same weight undergoing the same procedure (due to genetic variability in opioid metabolism, receptor sensitivity, pain threshold, anxiety, pre-operative opioid tolerance); a fixed-dose nurse-administered schedule cannot accommodate this variability; PCA allows the patient to self-administer small boluses when pain exceeds their individual threshold → rapid titration to individual analgesic requirement Standard PCA parameters (morphine IV): Parameter Standard Value (Morphine) Rationale Bolus dose 1 mg morphine (range 0.5– 2.5 mg) Small enough that a single extra dose does not cause respiratory depression; large enough to provide meaningful analgesia; in elderly >70: 0.5–1 mg; opioid-tolerant patients may need 2–2.5 mg Lockout interval 5 minutes Time to peak effect of IV morphine (5–10 min); prevents stacking before previous dose has taken effect; shorter lockout → ↑ overdose risk; longer → ↑ inadequate analgesia Background (continuous) infusion NOT routinely recommended (0 mg/h) Background infusion → ↑ opioid accumulation during sleep → ↑ respiratory depression risk (ISMP warning); reserved for opioid- tolerant patients (chronic opioid users) — match their baseline opioid requirements as background; children PCA-by-proxy: nurse or parent presses button → ↑ risk of overdose — NOT safe without HCA (healthcare professional-activated) 1-hour limit (or 4-hour limit) 10–20 mg/h (cumulative safety limit) Prevents excessive cumulative dosing; alerts nursing staff to reassess patient Concentration Morphine 1 mg/mL Standard concentration; errors occur with non-standard concentrations Opioid selection for PCA: Morphine — standard; active metabolite morphine-6-glucuronide (M6G) accumulates in renal failure → prolonged sedation; hydrophilic → slower onset (10–15 min) → higher bolus requirements Fentanyl — lipophilic → faster onset (5–7 min) → better titration; no active metabolites; preferred in renal failure; bolus 20–25 mcg (lockout 5 min) Oxycodone — intermediate lipophilicity; active metabolite oxymorphone; oral bioavailability 60–87% → oral oxycodone PCA available in some centres Hydromorphone — 5–7× more potent than morphine; active 3-glucuronide metabolite (accumulates in renal failure); bolus 0.2–0.4 mg PCA safety features: anti-reflux one-way valve (prevents siphoning of opioid into IV fluid bag); anti-tamper device; programmable lockout (cannot override); nurse override key (for loading dose); alarmed when reservoir low; dedicated PCA IV line (do NOT co-infuse other IV drugs — bolus of flush pushes PCA opioid → inadvertent overdose); monitoring: sedation score (Ramsay or RASS) + RR + SpO₂ (continuous overnight in high-risk patients) C. Multimodal Analgesic Strategy — Major Abdominal Surgery 3 marks Timing Intervention Rationale Pre-operative Celecoxib 400 mg PO + gabapentin 600 mg PO (pre-emptive analgesia); patient education and expectations; mark and plan regional technique; consent for epidural or TAP block Pre-emptive analgesia: giving analgesics before surgical injury → prevents central sensitisation before it occurs (more effective than treating established sensitisation post-op) Intraoperative Thoracic epidural (T6–T9 for upper abdominal; T9–T12 for lower) + TIVA propofol-remifentanil OR LA wound infiltration/TAP block at end; IV paracetamol 1g at induction; IV ketorolac 15–30 mg at wound closure; sub-anaesthetic ketamine 0.3 mg/kg/h infusion during surgery; dexamethasone 8 mg at induction (PONV + reduces pain); tranexamic acid (if applicable — ↓ blood loss) Epidural provides best post-op analgesia for open abdominal surgery; TAP block for laparoscopic; ketamine infusion → reduces opioid consumption 25–40% and PONV Postoperative Epidural infusion (bupivacaine 0.1% + fentanyl 2 mcg/mL) at 6–12 mL/h (if epidural in situ) OR PCA morphine/oxycodone (if no epidural); regular paracetamol 1g QDS; regular celecoxib 200 mg BD (if no contraindication — avoid in anastomotic bowel surgery — anastomotic leak risk); gabapentin 300 mg BD; breakthrough: oramorph 5–10 mg oral or morphine 2.5 mg IV; VAS assessment 4-hourly Regular non-opioid base → reduces opioid requirements 20–40%; epidural significantly reduces pulmonary complications, ileus, and hospital stay in open abdominal surgery (Kehlet 1999) ★ Examiner's Pearl WHO ladder adapted for acute pain: use in REVERSE (Step 3 first → step down). PCA standard: morphine 1 mg bolus, 5 min lockout, NO routine background infusion (↑ respiratory depression risk during sleep). Renal failure: avoid morphine (M6G accumulation) → use fentanyl. Multimodal strategy for major abdominal: epidural (best for open) + paracetamol + NSAID/COX-2 + gabapentin + ketamine infusion + dexamethasone = reduces opioid requirements 40–50%. Pre-emptive analgesia: given BEFORE surgical injury → prevents central sensitisation. References: Kehlet H, Dahl JB. The value of ""multimodal"" or ""balanced analgesia"" in postoperative pain treatment (Anesth Analg 1993;77:1048-1056). Macintyre PE. Safety and efficacy of patient-controlled analgesia (Br J Anaesth 2001;87:36-46). WHO. Cancer Pain Relief, 1986. Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 64."

"anaesthetic drug properties for ECT and comparison of induction agents [4] (c) Special considerations and contraindications in ECT [2]. A. Physiological Responses to ECT 4 marks ⚙ Core Concept ECT delivers a brief electrical stimulus to the brain to induce a generalised seizure — the therapeutic agent is the seizure itself (not the electrical stimulus). The anaesthetic challenge is to: (1) provide rapid onset unconsciousness and profound amnesia; (2) provide adequate muscle relaxation (to prevent orthopaedic injury from convulsions) without suppressing the seizure; (3) manage significant autonomic haemodynamic swings; (4) allow rapid recovery for outpatient/day-case scheduling. (Fink M — ECT pharmacology; NICE guidelines ECT; Miller's Anaesthesia 9th Ed) Phase Physiological Response Mechanism Clinical Significance / Management Immediately pre-stimulus (vagal phase) Brief parasympathetic response: ↓ HR, brief asystole (seconds), ↓ BP Cortical activation of vagal nuclei before generalised seizure Transient — usually self-limiting in seconds; atropine 0.3–0.6 mg IV (or IM 30 min before) if significant bradycardia historically; now some centres use glycopyrrolate pre-medication; continuous ECG monitoring essential During seizure (sympathetic phase) Massive sympathetic surge: ↑↑ HR (tachycardia 25–30%), ↑↑ BP (MAP ↑ 30–50%), ↑ cerebral blood flow, ↑ ICP, ↑ intraocular pressure, ↑ intragastric pressure; arrhythmias (PVCs, SVT) Generalised tonic-clonic seizure → massive central sympathetic discharge + catecholamine release (adrenaline ↑ 5–15× above baseline) The haemodynamic surge is the most significant risk — in patients with IHD, aortic aneurysm, or recent MI, the surge can trigger ischaemia or dissection; β-blockers (esmolol 1–2 mg/kg IV 2 min before stimulus OR metoprolol 1–2 mg IV) effectively blunt the haemodynamic response without compromising seizure quality; esmolol preferred (ultra-short-acting β₁ blocker — does not prolong stimulus block duration) Post-ictal phase Parasympathetic rebound: bradycardia, ↓ BP; then recovery; may have transient confusion, agitation, headache, myalgia, ↑ PONV; post-ictal apnoea (1–2 min) → maintain oxygenation by bag- mask ventilation Post-seizure cortical inhibition; parasympathetic rebound Maintain airway support; O₂ supplementation; anti-emetics pre-medication (ondansetron); PONV prophylaxis important (frequent treatments — up to 3× per week); headache: paracetamol; agitation: midazolam 1–2 mg IV; recovery area monitoring minimum 30 min Cerebral effects ↑ CMRO₂ during seizure (↑ 3–5×); ↑ CBF (CMRO₂-coupled); ↑ ICP; ↑ BBB permeability; post-ictally: ↓ CMRO₂ (post-ictal suppression on EEG) Generalised cortical neuronal firing → massive ↑ O₂ demand → CBF ↑ to match; ICP elevation during seizure is transient and usually well- tolerated by patients with normal ICP Raised ICP = RELATIVE contraindication (see below); ↑ glucose (stress response + sympathetic activation → glycogenolysis); monitor BGL in diabetic patients B. Ideal ECT Anaesthetic Agent Properties and Comparison 4 marks Ideal properties of induction agent for ECT: rapid onset (for amnesia and comfort); rapid recovery (ECT done 2–3× weekly in outpatients — rapid return to baseline); minimal anticonvulsant effect (must not suppress the therapeutic seizure — seizure duration target ≥20–25 seconds; EEG seizure duration target ≥25 seconds); minimal cardiovascular depression; antiemetic properties (PONV frequent in ECT); amnesic; no myalgia Agent Anticonvulsant Effect Recovery ECT Suitability Methohexitone (methohexital) — gold standard where available Minimal anticonvulsant effect (LOWEST of all barbiturates at ECT doses); may have mild proconvulsant effect (epileptiform activity on EEG) Rapid (shorter duration than thiopentone) PREFERRED agent for ECT; seizure duration consistently longest with methohexitone; 1–1.5 mg/kg; pain on injection; not widely available in all countries (supply issues) Propofol SIGNIFICANT anticonvulsant effect — consistently reduces seizure duration by 30– 50% compared to methohexitone; ↑ seizure threshold; higher stimulation required Excellent rapid recovery; antiemetic; preferred for PONV-prone patients Second-line (or preferred in some centres for PONV); acceptable if ECT team adjusts stimulus energy upward to compensate; avoid if very short ictal duration is a persistent problem Thiopentone Anticonvulsant (more than methohexitone, less than propofol) Moderate (hangover) Acceptable alternative when methohexitone unavailable; longer recovery than propofol Etomidate Minimal anticonvulsant effect; may ↑ seizure duration Rapid Used when prolonging seizure duration is desirable (prior short seizures with propofol); significant myoclonus on induction (alarm/distress patient); adrenocortical suppression limits frequent use (ECT 3×/week → cumulative adrenal suppression) Ketamine No significant anticonvulsant effect; mild Moderate Not generally preferred; ↑ BP during sympathetic surge → dangerous in Ketamine No significant anticonvulsant effect; mild proconvulsant Moderate (emergence reactions in ECT setting are problematic) Not generally preferred; ↑ BP during sympathetic surge → dangerous in cardiac patients; emergence reactions unpleasant; may be considered if all other agents fail to produce adequate seizure Muscle relaxant for ECT Succinylcholine 0.5–1 mg/kg (standard — complete paralysis within 60s; prevents injury from motor convulsions; allows monitoring of seizure via unparalysed forearm — inflate BP cuff BEFORE succinylcholine to isolate distal motor activity → visible in isolated unparalysed limb = ""modified cuff technique""); mivacurium or rocuronium (+ sugammadex) for pseudocholinesterase deficiency C. Special Considerations and Contraindications 2 marks Absolute contraindications: raised intracranial pressure (↑ ICP during seizure → herniation risk); space-occupying intracranial lesion; recent MI (within 3 months — haemodynamic surge risk); recent haemorrhagic or ischaemic stroke (within 3 months) Relative contraindications: severe cardiovascular disease (manage haemodynamic surge with esmolol); aortic or cerebral aneurysm (↑ rupture risk from BP surge — discuss with MDT); unstable spinal fractures; retinal detachment; recent bowel or bladder surgery (↑ intragastric pressure); severe osteoporosis (fracture risk from convulsions — ensure adequate NMB); pacemakers (ECT stimulus may interfere — use pacemaker-proof ECT machine or reprogram pacemaker to asynchronous mode before ECT) Drug interactions: lithium (↑ seizure duration and confusion — hold lithium night before ECT; ECT + lithium combination may cause prolonged seizures); monoamine oxidase inhibitors (MAOIs) — ECT + MAOIs → hypertensive crisis; generally stop MAOIs 2 weeks before ECT; benzodiazepines and anticonvulsants (↑ seizure threshold → shorten seizure duration → reduce ECT effectiveness; consider tapering dose before ECT treatment course) ★ Examiner's Pearl ECT autonomic sequence: initial vagal phase (bradycardia) → massive sympathetic surge (↑ HR 25%, ↑ MAP 30–50%) → post-ictal parasympathetic rebound. Haemodynamic surge management: esmolol 1–2 mg/kg IV 2 min before stimulus (preferred — ultra-short β₁ blocker). Best agent for ECT: methohexitone (least anticonvulsant effect → longest seizure); propofol ↓ seizure duration 30–50% (significant anticonvulsant → second-line). ECT NMB: succinylcholine 0.5–1 mg/kg + modified cuff technique. Lithium: hold night before (↑ seizure duration and confusion). References: Fink M. Convulsive therapy — a review of the first 55 years. J Affect Disord 2001;63:1-15. Avramov MN et al. Effects of methohexitone, propofol, and etomidate on seizure duration and recovery (Anesth Analg 1995;81:596-602). NICE guidelines: Electroconvulsive Therapy (ECT) — TA59. Miller RD et al. Miller's Anaesthesia, 9th Ed."

"of accidental hypothermia in the emergency setting [3] (c) Targeted temperature management (TTM) after cardiac arrest — evidence and current protocol [3]. A. Classification and Physiological Effects of Hypothermia 4 marks ⚙ Core Concept Hypothermia (core temperature <35°C) is classified by severity. Its physiological effects are multiorgan and profoundly affect anaesthetic drug requirements, coagulation, cardiac rhythm, and metabolic function. Perioperative hypothermia is common, preventable, and associated with significant morbidity. Conversely, therapeutic hypothermia exploits the cerebral and cardiac protective effects of cooling after cardiac arrest. (Sessler DI — perioperative hypothermia; Hypothermia After Cardiac Arrest Study Group HACA trial; TTM2 trial; Miller's Anaesthesia 9th Ed) Classification Core Temperature Clinical State Mild 32–35°C Shivering, tachycardia, hypertension, ↑ metabolic rate (compensating), confusion, dysarthria Moderate 28–32°C Shivering ceases (thermoregulation overwhelmed), bradycardia, ↓ CO, hypotension, AF, altered consciousness, paradoxical undressing Severe <28°C VF (highly likely <28°C), cardiac arrest, coma, no reflexes, fixed dilated pupils (may mimic death) Profound <20°C Complete cardiac arrest, isoelectric EEG, complete metabolic suppression Organ System Effect of Hypothermia Anaesthetic Relevance Cardiovascular ↓ HR; ↑ PR, QRS, QT intervals; J-wave (Osborn wave) on ECG at <30°C; AF at <32°C; VF at <28°C; ↓ CO; vasoconstriction (mild hypothermia) → ↑ SVR → ↑ BP initially; then vasodilation + ↓ CO at severe hypothermia Arrhythmias resistant to drugs at <30°C (drugs ineffective until rewarmed); DC cardioversion preferred; do NOT give repeated antiarrhythmic doses; VF at <28°C → CPR + rewarm to >30°C before expecting ROSC Respiratory ↓ RR; ↓ tidal volume; ↑ PaCO₂ (at 37°C correction); shift of ODC LEFT (↑ Hb affinity for O₂ → ↓ O₂ release to tissues); bronchospasm; loss of airway protective reflexes (aspiration risk) Apparent PaCO₂ may be misleading if not temperature-corrected; maintain normocarbia (at actual body temperature — alpha-stat vs pH- stat management on CPB) Neurological ↓ CMRO₂ (6–7% per 1°C reduction — protective); ↓ CBF; loss of consciousness at ~32°C; isoelectric EEG at <20°C; ""cold narcosis"" Reduced anaesthetic requirements (MAC reduced 5% per °C fall); propofol/opioid dose reduction needed; may not need anaesthesia at severe hypothermia Coagulation Enzyme-dependent coagulation cascade slowed (reaction rates ↓ with ↓ T); platelet dysfunction (sequestration + ↓ activation); coagulopathy worsened by acidosis (lethal triad: hypothermia + acidosis + coagulopathy in trauma) TEG/ROTEM: run at 37°C (not body temperature) → may underestimate coagulopathy; give FFP, cryoprecipitate; correct hypothermia itself is the most effective coagulopathy treatment Pharmacological ↓ Hepatic metabolism (↓ enzymatic activity) → ↑ drug half-lives (propofol, opioids, NMBDs); ↓ renal elimination; ↑ protein binding for some drugs → ↓ free drug fraction; NMB onset longer, recovery prolonged (at hypothermia) Reduce drug doses by 20–30% per 3°C below 37°C; prolonged NMB effect → delayed extubation; careful titration B. Management of Accidental Hypothermia 3 marks ""No one is dead until warm and dead"" — core principle: VF in severe hypothermia may be refractory to defibrillation until core temperature >30°C; apparent death must be confirmed only after full rewarming to >32–35°C (unless obviously fatal injury or prolonged warm cardiac arrest) Mild hypothermia (32–35°C): passive external rewarming (warm environment, insulation); active external rewarming (warmed blankets, forced-air warming — Bair Hugger, radiant heat); warm IV fluids (40–42°C); warm humidified O₂; monitor core temperature (rectal/oesophageal thermometer — oral/tympanic unreliable); rate of rewarming 0.5–2°C/hour Moderate-severe hypothermia (<32°C) with pulse: active external rewarming in ICU; warm humidified O₂ (via mask or ETT); warm IV fluids; warmed bladder irrigation; warmed pleural/peritoneal lavage if other methods failing; avoid muscle exertion (↑ O₂ demand); gentle patient handling (VF triggered by movement at <32°C); continuous cardiac monitoring; magnesium 2 g IV (raises VF threshold, reduces VF at <30°C) Severe hypothermia (<28°C) with cardiac arrest: continuous CPR (2:15 compression:ventilation at severe hypothermia — lower rate acceptable as CO₂ production ↓); do NOT give drugs until temperature >30°C (drugs accumulate + ineffective in cold); defibrillation: one shock attempt — if no ROSC, defer further shocks until >30°C; ECMO/ECLS (extracorporeal life support/ECPR) is the definitive rewarming technique for cardiac arrest with severe hypothermia — provides 4–6°C/hour rewarming + cardiac support; the highest-profile survival reports in severe hypothermic arrest involve ECMO rewarming; core rewarming takes priority over limb rewarming (prevent afterdrop — peripheral vasodilation during rewarm flushes cold acidotic blood to the core → transient further drop in core temperature) C. Targeted Temperature Management (TTM) After Cardiac Arrest 3 marks Rationale: post-cardiac arrest brain injury (PCABI) is the leading cause of death in successfully resuscitated patients; cerebral reperfusion injury occurs in the minutes-hours after ROSC (reactive oxygen species, excitotoxicity, apoptotic cascades, mitochondrial dysfunction, cerebral oedema); hypothermia → ↓ CMRO₂ (6–7%/°C) + ↓ excitatory neurotransmitter release + ↓ ROS production + ↓ inflammatory cascade → neuroprotection HACA trial (NEJM 2002) and Bernard trial (NEJM 2002): seminal trials; mild therapeutic hypothermia to 32–34°C for 12–24h after OHCA (out-of-hospital cardiac arrest) with VF → ↑ survival and ↑ neurological recovery; generated global adoption of post-arrest therapeutic hypothermia (TH) TTM trial (Nielsen et al., NEJM 2013): targeted temperature 33°C vs 36°C after OHCA → NO DIFFERENCE in mortality or neurological outcome; conclusion: preventing fever (hyperthermia) after cardiac arrest may be as important as active cooling; this shifted practice toward ""TTM"" (avoiding fever = target ≤36°C) rather than mandatory cooling to 33°C TTM2 trial (Dankiewicz et al., NEJM 2021): hypothermia 33°C vs normothermia (avoid fever ≤37.8°C) after OHCA → NO DIFFERENCE in all-cause mortality at 6 months (primary endpoint); hypothermia 33°C associated with ↑ arrhythmias; current 2023 ILCOR/ERC recommendations: maintain normothermia (36– 37.5°C) and actively prevent fever for at least 72h after cardiac arrest; routine active cooling to 33°C is no longer recommended for unselected OHCA patients based on TTM2 Current TTM protocol (post-TTM2): maintain core temperature 36–37.5°C; use surface or intravascular cooling devices to prevent fever; targeted temperature monitoring (oesophageal or rectal thermometer — not peripheral); target for at least 72 hours; patients who remain in cardiac arrest after ROSC despite adequate haemodynamics: consider 33°C cooling while awaiting further evidence ★ Examiner's Pearl Hypothermia classification: mild 32–35°C (shivering); moderate 28–32°C (shivering ceases, AF); severe <28°C (VF, cardiac arrest). J-wave (Osborn wave): pathognomonic ECG finding at <30°C. ""No one is dead until warm and dead."" Drugs ineffective <30°C — defer; one defibrillation attempt then ECMO rewarming. TTM evolution: HACA 2002 (33°C beneficial) → TTM 2013 (33°C = 36°C) → TTM2 2021 (normothermia = 33°C, ↑ arrhythmias with 33°C); current: prevent fever ≤37.8°C × 72h. References: HACA Study Group. Mild therapeutic hypothermia to improve neurological outcome (NEJM 2002;346:549-556). Nielsen N et al. TTM trial (NEJM 2013;369:197-206). Dankiewicz J et al. TTM2 trial (NEJM 2021;384:2321-2333). Sessler DI. Perioperative thermoregulation (Anesthesiology 1997;87:988-1002). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"abnormalities in cirrhosis and their perioperative management [4]. Outline the anaesthetic implications of hepatic encephalopathy [3]. ⚙ Core Concept Chronic liver disease presents the anaesthesiologist with a unique constellation of challenges — a seemingly ""normal"" PT/INR does not mean the liver is producing adequate haemostatic proteins (it also makes anticoagulant proteins — a ""rebalanced"" but fragile haemostasis); severe portopulmonary hypertension may preclude surgery; and encephalopathy creates profound neuropharmacological sensitivity. (Pugh RN — Child-Pugh score; Kamath PS — MELD; Gines P — cirrhosis complications; Miller's Anaesthesia 9th Ed) A. Child-Pugh and MELD Scoring 3 marks Parameter Child-Pugh Score (1 point) Child-Pugh Score (2 points) Child-Pugh Score (3 points) Bilirubin (μmol/L) <34 34–51 >51 Albumin (g/L) >35 28–35 <28 PT prolongation (seconds) <4 4–6 >6 Ascites None Mild (controlled) Moderate/severe (refractory) Encephalopathy None Grade I–II Grade III–IV Class Total Score 1-Year Survival Perioperative Mortality (major surgery) Class A (well-compensated) 5–6 95% 2–10% Class B (significant dysfunction) 7–9 75% 10–30% Class C (decompensated) 10–15 45–50% 50–82% MELD score (Model for End-stage Liver Disease): MELD = 9.57 × ln(creatinine) + 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 6.43; range 6–40; higher = worse prognosis; MELD >15 → 30-day perioperative mortality >15%; MELD >20 → elective surgery generally contraindicated; used for liver transplant priority listing; MELD-Na incorporates sodium concentration (more accurate predictor); more accurate than Child-Pugh for prognosis because it uses continuous variables and accounts for renal function B. Coagulation Abnormalities in Cirrhosis 4 marks The ""rebalanced haemostasis"" concept: the liver produces BOTH procoagulant factors (I, II, V, VII, VIII [endothelium], IX, X, XI, XIII, fibrinogen) AND anticoagulant proteins (protein C, protein S, antithrombin III); in cirrhosis, BOTH are reduced; PT and INR are prolonged because they only test procoagulant factors (measured by the extrinsic pathway test); PT/INR does NOT accurately reflect overall haemostatic capacity in cirrhosis because the ANTICOAGULANT proteins are equally reduced (the system is rebalanced); therefore: a prolonged INR in cirrhosis does NOT necessarily indicate a bleeding tendency — the patient may have near-normal clot formation when both arms of haemostasis are tested (thromboelastography reflects this better) Specific abnormalities: ↓ Synthesis of all clotting factors except Factor VIII (VIII is from endothelium + acute phase reactant → ↑ in cirrhosis) ↓ Fibrinogen (hypofibrinogenaemia) + dysfibrinogenaemia (abnormal fibrinogen structure) Thrombocytopenia (sequestration in enlarged spleen — hypersplenism + ↓ thrombopoietin production by liver) Platelet dysfunction (↑ nitric oxide + prostacyclin from endothelium → ↓ platelet activation) Hyperfibrinolysis (↓ α₂-antiplasmin, ↓ PAI-1 synthesis → ↑ fibrinolytic activity) Disseminated intravascular coagulation (DIC) in decompensated cirrhosis (low-grade chronic DIC) Perioperative management of coagulopathy in cirrhosis: avoid unnecessary FFP transfusion solely to correct INR — it does not improve haemostasis (because anticoagulant proteins also in FFP → rebalance is maintained); give FFP if active bleeding; cryoprecipitate/fibrinogen concentrate for fibrinogen <1.5 g/L; platelets transfusion if <50×10⁹/L for surgery; vitamin K 10 mg IV (if vitamin K deficiency component — common in cholestatic disease); TEG/ROTEM to guide goal-directed transfusion; tranexamic acid for hyperfibrinolysis; desmopressin (DDAVP) 0.3 mcg/kg for platelet dysfunction (↑ release of vWF from endothelium) C. Hepatic Encephalopathy — Anaesthetic Implications 3 marks Grading (West Haven criteria): Grade I — mild confusion, altered sleep; Grade II — lethargy, asterixis (flapping tremor); Grade III — marked confusion, somnolence; Grade IV — coma, unresponsive Pathophysiology: ↑ ammonia (from gut bacterial proteolysis + impaired hepatic clearance) → astrocyte swelling → cerebral oedema; GABA-like effects of ammonia; zinc and manganese accumulation Anaesthetic implications: ↑ sensitivity to all CNS depressants (opioids, benzodiazepines, propofol) — even small doses may precipitate or worsen encephalopathy; reduce all doses by 50–70%; avoid benzodiazepines if possible Impaired drug metabolism: all hepatically metabolised drugs (most anaesthetic agents) → prolonged effect; avoid long-acting benzodiazepines (diazepam active metabolites) Avoid increases in blood ammonia perioperatively: avoid excessive protein load, constipation (give lactulose), GI bleeding (treat promptly) Post-operative encephalopathy risk: 20–30% after major surgery in cirrhotic patients; ICU admission with neurological monitoring after major surgery Drug of choice for sedation in encephalopathic patient: propofol (no active metabolites, short-acting, predictable); avoid benzodiazepines; opioid choice: fentanyl (no active metabolites — preferred); avoid morphine (accumulation) and codeine ★ Examiner's Pearl Child-Pugh C (10–15): 50–82% perioperative mortality for major surgery; MELD >20 = elective surgery contraindicated. ""Rebalanced haemostasis"" — INR prolonged in cirrhosis does NOT mean haemorrhagic tendency (anticoagulant proteins equally ↓); TEG better reflects true haemostatic status. Hepatic encephalopathy: ↑ sensitivity to all CNS drugs → 50–70% dose reduction; avoid benzodiazepines; fentanyl preferred opioid (no active metabolites); propofol preferred sedative. References: Pugh RN et al. Transection of oesophagus for bleeding oesophageal varices (Br J Surg 1973;60:646-649). Kamath PS et al. MELD score (Hepatology 2001;33:464-470). Gines P et al. Cirrhosis (Lancet 2004;364:1749-1761). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"goals"" for patients with severe aortic stenosis [3]. Outline the anaesthetic management for non-cardiac surgery in a patient with severe AS [4]. ⚙ Core Concept Severe aortic stenosis (AS) is the commonest valvular lesion in older patients requiring non-cardiac surgery — with a prevalence of 5% in octogenarians. The fixed outflow obstruction creates a pressure-overloaded, hypertrophied, non-compliant LV that is extremely vulnerable to: rapid HR changes (impaired diastolic filling), vasodilation (fixed SV cannot compensate), and volume overload (stiff LV → flash pulmonary oedema). (Faggiano P — AS periop risk; Nishimura RA — ACC/AHA valve guidelines; Miller's Anaesthesia 9th Ed) A. Pathophysiology of Aortic Stenosis 3 marks Aetiology: calcific degenerative AS (most common — elderly; calcium deposits on tricuspid aortic valve leaflets); bicuspid aortic valve (congenital — presents at younger age 50–60 years); rheumatic AS (developing countries) Severity classification (AVA — aortic valve area; and mean gradient): mild: AVA >1.5 cm²; moderate: 1.0–1.5 cm²; severe: AVA <1.0 cm² (or <0.6 cm²/m² indexed) + mean gradient >40 mmHg + peak velocity >4 m/s; very severe: AVA <0.6 cm² or mean gradient >60 mmHg Pathophysiological sequence: calcified aortic valve → fixed obstruction to LV outflow → LV must generate markedly ↑ systolic pressure to eject across the stenotic valve → LV systolic pressure may reach 200–300 mmHg (vs aortic 120 mmHg) → chronic pressure overload → concentric LVH (↑ wall thickness — the Laplace compensation: ↑ thickness reduces wall stress: σ = Pr/2h) → consequences of LVH: ↓ LV compliance (stiff ventricle) → diastolic dysfunction → relies heavily on atrial contraction (""atrial kick"") for ventricular filling; loss of atrial kick (AF) → ↓ CO by 20–40% acutely Subendocardial ischaemia — even with normal coronary arteries: ↑↑ LV wall stress + ↑↑ O₂ demand (hypertrophied muscle) + ↓ coronary perfusion (↓ diastolic time, ↓ coronary driving pressure due to ↑ LVEDP compressing subendocardial vessels) Fixed stroke volume: the hypertrophied, stiff LV ejects a relatively fixed SV regardless of preload (non-responsive to Frank-Starling); CO = SV × HR → CO becomes HR-dependent Classic triad of severe AS symptoms (and their prognostic significance): Angina (survival 5 years without intervention); Syncope (survival 3 years — occurs when vasodilation during exercise is not compensated by ↑ CO → cerebral hypoperfusion); Heart failure (survival 1–2 years) B. Haemodynamic Goals for Severe AS 3 marks ⭐ Mnemonic — SSSR for Severe AS S inus rhythm (MAINTAIN) | S low HR (50–80 bpm) | S VR maintained (AVOID vasodilation) | R easonable preload (maintain — diastolic filling critical) Parameter Goal Reason Heart rate 50–80 bpm (SLOW — avoid tachycardia) ↑ HR → ↓ diastolic filling time → ↓ LVEDV → ↓ SV → ↓ CO in the stiff hypertrophied LV; also → ↓ coronary perfusion time → subendocardial ischaemia; tachycardia is THE most dangerous haemodynamic perturbation in severe AS; avoid atropine, ketamine, atracurium (histamine → tachycardia) Rhythm Sinus rhythm (MAINTAIN) Atrial kick provides 20–40% of LV filling in the stiff, non-compliant LV; AF → sudden loss of atrial kick → acute decompensation; AF should be treated urgently with cardioversion if haemodynamically compromised SVR MAINTAIN normal to slightly ↑ (avoid vasodilation) Fixed SV → CO = SV × HR; if SVR falls → MAP falls → diastolic BP falls → coronary perfusion falls → ischaemia → further ↓ SV; the LV cannot compensate for vasodilation by ↑ CO (fixed outflow obstruction + stiff ventricle); phenylephrine (pure α₁ — ↑ SVR without tachycardia) is the vasopressor of choice Preload MAINTAIN (avoid hypovolaemia) The stiff LV requires adequate filling (higher LVEDP) for adequate SV; hypovolaemia → ↓ SV → ↓ CO → hypotension cascade; BUT avoid fluid overload → ↑ LVEDP above 25 mmHg → ↑ LA pressure → pulmonary oedema (the stiff LV has very steep EDPVR — small ↑ in volume → large ↑ in pressure) Contractility MAINTAIN (avoid myocardial depression) The hypertrophied LV has limited contractile reserve; myocardial depressants (propofol, volatile agents at >1 MAC, thiopentone) → ↓ already compensated contractility → acute decompensation; titrate carefully C. Anaesthetic Management for Non-Cardiac Surgery 4 marks Pre-operative assessment: confirm severity (echo: AVA, mean gradient, LVEF); look for new symptoms (progression to symptomatic AS greatly ↑ perioperative risk); cardiology referral; consider TAVR (transcatheter aortic valve replacement) or SAVR before elective major non-cardiac surgery if AVA <1.0 cm² AND symptoms present (ACC/AHA Class I recommendation); if truly urgent non-cardiac surgery → proceed with careful haemodynamic management; discuss risk explicitly with patient and surgical team; elective surgery in asymptomatic AS with preserved LVEF: perioperative risk is acceptable (3–4%) if haemodynamic goals are maintained — discuss with cardiologist Monitoring: invasive arterial line (beat-to-beat BP — essential; even minor hypotension must be detected and treated immediately before ischaemic cascade begins); central venous line; TOE (transoesophageal echocardiography) intraoperatively if major surgery — monitors preload, wall motion abnormalities, valve gradients, ventricular function; consider pulmonary artery catheter or LiDCO/FloTrac for continuous CO monitoring Induction technique: SLOW and CAREFULLY TITRATED; avoid propofol bolus (sudden ↓ SVR + ↓ contractility → catastrophic hypotension); options: etomidate (most cardiovascularly stable — minimal SVR/contractility depression); if propofol: use very slowly (0.5–1 mg/kg over 5–10 min), titrated; thiopentone: acceptable in low doses; avoid ketamine (tachycardia); GA preferred over high-level neuraxial (epidural/spinal → ↓ SVR → ↓ MAP → ischaemic cascade); if spinal is required (e.g., hip replacement): low-dose hypobaric or isobaric bupivacaine, careful titration, phenylephrine infusion ready Maintenance: volatile agent at ≤0.5–1 MAC (↓ SVR + ↓ contractility at higher concentrations); TIVA with propofol (careful titration) + remifentanil; avoid tachycardia (beta-blockade if HR >80 — esmolol 10–25 mg IV); vasopressor of choice: phenylephrine 50–100 mcg boluses or infusion (↑ SVR without tachycardia); avoid atropine for bradycardia (phenylephrine + ↑ preload preferable); ↑ preload with IV fluid bolus if MAP falls; normocarbia; avoid acidosis ★ Examiner's Pearl Severe AS: AVA <1.0 cm², mean gradient >40 mmHg, peak velocity >4 m/s. Classic triad: angina (5yr survival), syncope (3yr), heart failure (1–2yr). Haemodynamic goals SSSR: Sinus rhythm + Slow HR (50–80) + SVR maintained + Reasonable preload. Vasopressor of choice: phenylephrine (pure α₁ — ↑ SVR, no tachycardia). Avoid: propofol bolus (↓ SVR + ↓ contractility), spinal (sudden ↓ SVR), tachycardia, atropine, hypotension. References: Nishimura RA et al. ACC/AHA Valve Guideline 2014 update (J Am Coll Cardiol 2014;63:e57-185). Faggiano P et al. Aortic valve stenosis in patients undergoing non-cardiac surgery (Eur J Anaesthesiol 2012;29:1-8). Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 67."

"implications — NMB sensitivity, drug interactions and choice of agents [4] (c) Myasthenic crisis vs cholinergic crisis — distinction and management [3]. ⚙ Core Concept Myasthenia gravis (MG) is the prototypic neuromuscular junction disorder — an autoimmune attack on the post-synaptic nAChR reduces functional receptor numbers → fatigable weakness. It creates extreme sensitivity to NDMBs, relative resistance to succinylcholine, and the potential for post-operative myasthenic crisis. Understanding the difference between myasthenic crisis and cholinergic crisis is a classic exam favourite. (Vincent A — MG pathophysiology; Baraka A — NMB in MG; Miller's Anaesthesia 9th Ed) A. Pathophysiology and Classification 3 marks Autoimmune mechanism: in 85% of generalised MG: autoantibodies (IgG) against nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction → antibody binding → complement-mediated receptor destruction + receptor crosslinking and internalisation + blockade of ACh binding site → ↓ functional nAChR number (by 70–90% in severe MG) → ACh released normally but fewer receptors available → impaired EPP (end-plate potential) → fails to reach threshold → action potential fails to propagate → no muscle contraction; the key hallmark: fatigable weakness (worsens with repeated effort as ACh depletes transiently — partial receptor blockade means marginal safety factor) Other antibodies: 10% anti-MuSK (muscle-specific kinase — anchors nAChRs at NMJ); 5% anti-LRP4; 5% seronegative Osserman Classification: Class I — ocular only (ptosis, diplopia); Class IIa — mild generalised; Class IIb — moderate generalised; Class III — acute severe (respiratory involvement); Class IV — chronic severe; Class V — intubated (crisis) Thymoma association: 10–15% of MG patients have thymoma (thymectomy → sustained remission in 25–30%; improvement in 50–60%); all patients with generalised MG should have CT chest to exclude thymoma B. Anaesthetic Implications 4 marks Agent / Consideration Effect in MG Recommendation NDMBs (rocuronium, vecuronium, atracurium) EXTREME sensitivity — profound block at 5–10% of normal dose; even standard ""intubation"" doses produce complete block lasting 4– 8× normal duration; the ↓ nAChR numbers → less receptors to be blocked → near-complete block with tiny doses If NDMB is essential: use 10–20% of normal intubating dose and titrate with TOF monitoring; cisatracurium/atracurium preferred (organ- independent elimination); have sugammadex available for emergency reversal of rocuronium; volatile or LA technique preferred to avoid NMBs entirely Succinylcholine RELATIVE RESISTANCE — requires LARGER than normal dose; the ↓ nAChR numbers means more drug needed to achieve adequate depolarisation for block; ED₉₅ approximately doubled If RSI required: succinylcholine 2 mg/kg (double normal dose); paradoxical response — may cause prolonged phase II block in MG patients on pyridostigmine (anticholinesterase → ↓ plasma cholinesterase → delayed succinylcholine hydrolysis); use with caution Pyridostigmine (anticholinesterase treatment) Inhibits all AChE (NMJ, plasma esterase) → ↓ plasma cholinesterase → prolongs succinylcholine; ↑ NMJ ACh → may partially restore NMJ function; CONTINUE perioperatively (stopping → ↑ weakness; but some anaesthetists hold morning dose to reduce secretions) CONTINUE pyridostigmine perioperatively; if held: restart IV equivalent dose ASAP; monitor for cholinergic effects (excessive secretions, bradycardia) Volatile anaesthetics ↓ Post-synaptic nAChR function (at NMJ) + direct muscle relaxant effect → potentiate NMJ block in MG; sevoflurane produces significant NMJ blockade at ≥1 MAC in MG patients Use lower concentrations (0.5–0.8 MAC); supplement with IV agents; consider TIVA with propofol + remifentanil + LA techniques to avoid volatile-induced NMJ depression Extubation criteria (critical in MG) MG patients have ↓ respiratory reserve; post-operative respiratory failure → myasthenic crisis common (20–30% after thymectomy); TOF ratio ≥0.9 is NOT sufficient alone in MG Extubate only when: (1) TOF ratio ≥0.9; (2) VC ≥15 mL/kg; (3) sustained head lift ≥5 sec; (4) MIP (maximal inspiratory pressure) >-20 cmH₂O; (5) patient fully alert; plan ICU admission after thymectomy or major surgery C. Myasthenic Crisis vs Cholinergic Crisis 3 marks Feature Myasthenic Crisis Cholinergic Crisis Cause Insufficient ACh effect at NMJ — disease deterioration, infection, surgery, stress, inadequate pyridostigmine Excess ACh — overdose of anticholinesterase (pyridostigmine overdose or too frequent dosing) Weakness pattern Fatigable weakness — gets worse with activity; ptosis, dysphagia, dysarthria, respiratory weakness Weakness that is CONSTANT (not fatigable) — muscle depolarisation block from excess ACh Pupils Normal or slightly dilated MIOSIS (pinpoint — muscarinic effect of excess ACh) Secretions Dry mouth (insufficient cholinergic tone) SALIVATION, lacrimation, rhinorrhoea, bronchospasm, diarrhoea (muscarinic excess — DUMBELS: Diarrhoea, Urination, Miosis, Bradycardia, Emesis, Lacrimation, Salivation) Edrophonium IMPROVES weakness (↑ NMJ ACh → improves transmission) WORSENS weakness (further ↑ ACh → further depolarisation test (Tensilon test) block → more weakness); fasciculations worsen Management Secure airway (intubation/ICU); IVIG 2 g/kg over 5 days OR plasma exchange (PE) × 5 sessions (removes autoantibodies); ↑ pyridostigmine dose; immunosuppression; treat precipitant (infection → antibiotics); steroids long-term (prednisolone) STOP pyridostigmine; atropine for muscarinic symptoms; ICU support; airway management; allow AChE to recover over hours; resume pyridostigmine at lower dose when recovered ★ Examiner's Pearl MG mechanism: IgG anti-nAChR antibodies → receptor destruction → ↓ functional receptors → fatigable weakness; nAChR reduced by 70–90% in severe MG. NDMBs: EXTREME sensitivity (use 10–20% of normal dose). Succinylcholine: relative resistance (need 2 mg/kg). Myasthenic crisis vs cholinergic crisis: edrophonium IMPROVES myasthenic (↑ ACh effect at depleted receptors), WORSENS cholinergic (further excess ACh). Miosis = cholinergic crisis (DUMBELS). Treatment: IVIG or plasma exchange (remove autoantibodies). References: Vincent A et al. Myasthenia gravis (Lancet 2001;357:2122-2128). Baraka A. Anaesthesia and critical care of myasthenia gravis (Middle East J Anaesthesiol 1992;11:415-447). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"and optimisation [3]. Discuss intraoperative ventilation strategy and postoperative pulmonary complication prevention [4]. ⚙ Core Concept COPD (FEV₁/FVC <0.70 post-bronchodilator) affects 10–15% of adult surgical patients — pulmonary complications are the most common cause of prolonged hospital stay after major surgery. Pre-operative optimisation, careful ventilation strategy, and targeted post-operative respiratory support are the pillars of COPD perioperative management. (GOLD 2023 guidelines; Arozullah AM — pulmonary risk index; Miller's Anaesthesia 9th Ed) A. Spirometric Patterns and GOLD Classification 3 marks Obstructive pattern: FEV₁/FVC <0.70 (post-bronchodilator confirms obstruction); ↓ FEV₁ (flow-limited expiration from airway collapse); FVC may be normal or ↓; air trapping → ↑ RV; hyperinflation → ↑ TLC; diffusion capacity (DLCO) ↓ in emphysema (alveolar surface area ↓) GOLD Stage FEV₁ (% predicted) Symptoms Perioperative Risk GOLD 1 (Mild) ≥80% Chronic cough, sputum — often absent Low GOLD 2 (Moderate) 50–79% Dyspnoea on exertion, ↑ exacerbations Moderate GOLD 3 (Severe) 30–49% Significant dyspnoea, frequent exacerbations High GOLD 4 (Very severe) <30% Severe dyspnoea at rest, respiratory failure, cor pulmonale Very high — consider deferral B. Perioperative Assessment and Optimisation 3 marks Assessment: spirometry (FEV₁, FVC, FEV₁/FVC, DLCO); ABG (chronic CO₂ retention — PaCO₂ >6 kPa = ↑ risk; renal compensation of respiratory acidosis); CXR (hyperinflation, bullae — risk of pneumothorax with positive pressure ventilation); echocardiography (pulmonary hypertension, RV function — cor pulmonale); exercise tolerance (6-minute walk test, CPET); Arozullah pulmonary risk index (identifies high-risk patients) Optimisation (minimum 6–8 weeks before elective surgery): smoking cessation (at least 8 weeks — less than this does not ↓ secretions, may transiently ↑ secretions); optimise bronchodilators (LABA + LAMA + ICS per GOLD guidelines — ensure inhaler technique correct); treat exacerbation with antibiotics + oral steroids if indicated; chest physiotherapy to clear secretions; treat cor pulmonale (diuretics); CPAP or NIV for OHS component; outpatient pulmonary rehabilitation (6 weeks → ↑ FEV₁, ↑ exercise tolerance, ↑ QoL) C. Intraoperative Ventilation and Post-operative Prevention 4 marks Intraoperative ventilation strategy: avoid high-pressure ventilation (dynamic hyperinflation — ""breath stacking"" — already compromised compliance + air trapping → auto-PEEP → cardiovascular collapse); settings: low RR (10–12/min), prolonged expiratory time (I:E ratio 1:3 to 1:4 — allows complete exhalation before next breath); TV 6–8 mL/kg IBW; low PEEP (auto-PEEP from gas trapping may exceed set PEEP — disconnect airway briefly before PEEP adjustment to measure intrinsic PEEP); monitor capnography carefully (dead space ↑ → ETCO₂ may underestimate PaCO₂ significantly — check ABG periodically); regional anaesthesia avoids GA-related complications where feasible (thoracic epidural for thoracotomy; spinal for lower limb) Post-operative pulmonary complication prevention (ARISCAT score — risk stratification): lung recruitment manoeuvres; low tidal volume ventilation; early extubation (prolong intubation → VAP → worse outcomes); chest physiotherapy; early mobilisation; adequate analgesia (multimodal — thoracic epidural/PVB reduces splinting → ↓ atelectasis); NIV/CPAP early if SpO₂ <94% on O₂; targeted O₂ delivery (SpO₂ 88–92% in chronic CO₂ retainers — higher O₂ → suppresses hypoxic drive → ↑ CO₂ retention → hypercapnic encephalopathy); incentive spirometry ★ Examiner's Pearl COPD spirometry: FEV₁/FVC <0.70 (post-bronchodilator); GOLD 4: FEV₁ <30% → very high perioperative risk. Intraoperative: low RR, prolonged expiratory time (I:E 1:3 to 1:4) to prevent air trapping and auto-PEEP. Oxygen target in chronic CO₂ retainer: SpO₂ 88–92% (not 98–100% — hypoxic drive suppression → ↑ CO₂ retention). Smoking cessation: minimum 8 weeks before elective surgery. References: GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global Strategy for Diagnosis, Management, and Prevention of COPD, 2023. Arozullah AM et al. Multifactorial risk index for predicting postoperative respiratory failure (Ann Surg 2000;232:242-253)."

"management [4] (b) Hypothyroid coma — clinical features and anaesthetic management [3] (c) Anaesthetic considerations for thyroid surgery including airway management [3]. ⚙ Core Concept Thyroid disease spans a wide spectrum from subclinical abnormalities (common — 5–10% of population) to life-threatening crises. Thyroid storm and hypothyroid coma are both anaesthetic emergencies. Thyroid surgery presents unique airway challenges — compression, displacement, and post- operative haematoma. (Burch HB, Wartofsky L — thyroid storm score; Ringel MD; Miller's Anaesthesia 9th Ed) A. Thyroid Storm — Precipitants, Features and Management 4 marks Precipitants: surgery or trauma (especially on the thyroid itself — not rendering patient euthyroid before surgery); infections (most common); radioactive iodine (transient thyrotoxicosis from radiation thyroiditis); contrast media; parturition; non-compliance with antithyroid drugs; amiodarone (40% iodine by weight) Burch-Wartofsky Point Scale (>45 points = likely thyroid storm): temperature (scored 0–15 points based on severity of hyperthermia); CNS effects (mild agitation 10, delirium/psychosis 20, coma 30); GI/hepatic dysfunction (diarrhoea/nausea/vomiting 10, jaundice 20); cardiovascular (HR, AF, cardiac failure — up to 45 points from HR component alone); precipitant identified (10 points) Management (remember ""BATHED""): B eta-blockers: propranolol 60–80 mg PO q4h (or esmolol infusion IV if PO not possible) — controls tachycardia and peripheral T4→T3 conversion; symptomatic control A ntithyroid drugs: propylthiouracil (PTU) 500–1000 mg loading then 250 mg q4h (preferred — also blocks T4→T3 peripheral conversion) OR methimazole 60–80 mg/day; blocks new hormone synthesis T hionamide THEN iodine (Lugol's iodine 8 drops q6h): MUST give antithyroid drug first (at least 1 hour before iodine) — iodine initially provides substrate for new hormone synthesis if given without antithyroid drug (""Jod-Basedow"" effect); after 1h: Lugol's iodine blocks hormone release (Wolff-Chaikoff effect) H ydrocortisone 100 mg IV q8h: blocks T4→T3 conversion; covers relative adrenal insufficiency (thyroid storm depletes adrenal reserves); anti- inflammatory E xpressive cooling: paracetamol (NOT aspirin — displaces T4 from binding proteins → ↑ free T4); ice packs; cooling blanket; target temperature <38.5°C D efeat the cause: treat precipitant (antibiotics if infection; manage surgical complication) B. Hypothyroid Coma 3 marks Clinical features: progressive drowsiness → coma; hypothermia; bradycardia; ↓ BP; hyponatraemia (SIADH); hypoglycaemia; hypoventilation (hypercapnia — hypoventilation from ↓ respiratory drive); delayed deep tendon reflexes (""hung-up reflexes""); myxoedema facies; non-pitting oedema; periorbital oedema; ↑ CK; macroglossia (airway risk); myopericardial effusion Anaesthetic management: extreme sensitivity to all CNS depressants and opioids (↓ elimination, ↑ pharmacodynamic sensitivity) → use 25–50% of normal doses; hypothermia → ↓ MAC, ↓ drug requirements; hyponatraemia (Na ⁺ <120) → seizure risk → correct slowly (hypertonic saline if symptomatic, no faster than 0.5–1 mEq/L/hour); airway: macroglossia + myxoedema tissues → difficult airway — have videolaryngoscope and surgical airway kit immediately available; treatment: levothyroxine 200–500 mcg IV loading (cautiously — rapid correction in cardiac disease may precipitate MI); hydrocortisone 100 mg IV (adrenal insufficiency frequently co-exists); active rewarming; HDU/ICU admission C. Anaesthetic Considerations for Thyroid Surgery 3 marks Airway assessment: CT neck/thorax — assess tracheal deviation and compression (intrathoracic goitre); assess tracheal calibre at narrowest point; if tracheal compression >50% → awake fibreoptic intubation; if tracheal softening (tracheomalacia from longstanding compression) → post-operative airway collapse risk even after tumour removal Induction and intubation: videolaryngoscopy or awake FOI for anticipated difficult airway; reinforced (armoured/spiral wire) ETT (to prevent kinking from surgical manipulation); intraoperative neuromonitoring of recurrent laryngeal nerve (RLN) — avoid NMBs or use TOF-guided ultra-light NMB to allow NMM monitoring; tube position may be intermittently assessed by laryngeal EMG Post-operative haematoma (the most feared complication): occurs in 1–2% within 6h of surgery; sudden neck swelling + stridor + dyspnoea → immediately release skin sutures at bedside (or bring patient back to theatre) — this relieves the haematoma pressure and may restore airway; have surgical team immediately available during the first 6h; if airway compromised → attempt laryngoscopy (oedema may prevent view) → consider awake tracheostomy if cannot intubate; have CICO equipment immediately at the bedside in recovery ★ Examiner's Pearl Thyroid storm treatment BATHED: Beta-blocker → Antithyroid → Thionamide then iodine (1h gap — Jod-Basedow risk) → Hydrocortisone → Expressive cooling → Defeat cause. Burch-Wartofsky >45 points = likely storm. Hypothyroid: extreme sensitivity to CNS depressants (25–50% dose); macroglossia → difficult airway. Thyroid haematoma: 1–2% in first 6h → release skin sutures immediately at bedside → restores airway in most cases. References: Burch HB, Wartofsky L. Life-threatening thyrotoxicosis — thyroid storm (Endocrinol Metab Clin NA 1993;22:263-277). Miller RD et al. Miller's Anaesthesia, 9th Ed."